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Using bilateral internal thoracic arteries (BITA) for coronary artery bypass grafting (CABG) 
has been suggested to improve survival compared to CABG using single internal thoracic 
arteries (SITA) for patients with advanced coronary artery disease. We used data from the 
Arterial Revascularisation Trial (ART) to assess long-term cost-effectiveness of BITA 
grafting compared to SITA grafting from an English health system perspective. 
Methods  
Resource use, healthcare costs and quality-adjusted life-years (QALYs) were assessed across 
10-years of follow-up. An intention-to-treat analysis of differences between trial arms was 
conducted.  Missing data were addressed using multiple imputation. Incremental cost-
effectiveness ratios were calculated with uncertainty characterised using non-parametric 
bootstrapping. Results were extrapolated beyond 10 years using Gompertz functions for 
survival and linear models for total cost and utility.  
Results  
Total mean costs at 10 years of follow-up were estimated at £17,594 in the BITA arm and 
£16,462 in the SITA arm (mean difference £1,133 95% CI £239 to £2,026, p= 0.015). Total 
mean QALYs at 10 years were 6.54 in the BITA are and 6.57 in the SITA arm (adjusted 
mean difference -0.01 95% CI -0.2 to 0.1, p= 0.883). The estimated probability of BITA 
grafting being cost-effective compared to SITA grafting was 33% over 10 years of follow-up 
assuming a cost-effectiveness threshold of £20,000. Mean costs extrapolated to life-time 
increased to £20,760 in the SITA arm and £21,925 in the BITA arm. Mean QALYs 
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probability of BITA being cost-effective at a £20,000 threshold increased to 51% when 
extrapolated to lifetime.  
Conclusions 
BITA grafting has significantly higher costs but similar quality-adjusted survival at 10 years 
compared to SITA grafting. Extrapolation suggests this could change over lifetime.   
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The treatment of coronary artery disease places a large economic burden on health care 
systems, with a substantial proportion of that cost arising from Coronary Artery Bypass 
Grafting (CABG).1 CABG using a single left internal thoracic artery (SITA) has been found 
to improve long-term survival and quality of life (QoL) and to be cost-effective in 
comparison to the alternative of drug-eluting stents- percutaneous coronary intervention 
(DES-PCI) for patients with severe coronary disease and patients with diabetes in a Dutch 
context.2 
The success of SITA grafting has raised interest in the use of bilateral internal thoracic 
arteries (BITA) grafting. A recent meta-analysis of 29 observational studies comparing BITA 
and SITA found BITA was associated with significantly improved long-term survival (HR 
0.78).3 However, no previous study has reported a comparison of quality of life, resource use 
and costs between SITA and BITA. 
The Arterial Revascularisation Trial (ART) was the first large randomized controlled trial to 
compare BITA grafting with SITA grafting and was designed with an integrated economic 
evaluation. Clinical outcomes of ART have recently been published, reporting no significant 
difference between the two groups for the primary outcome of death from any cause at 10 
years of follow-up.4 Interim analyses of costs from index admission to 1-year of follow-up 
and 5 years of follow-up have been published previously,5,6 finding that BITA grafting was 
associated with 9% higher costs after one year, primarily due to longer time in theatre and 
hospital stay and higher costs associated with sternal wound problems. No further cost 
differences were found from years 2 to 5, with healthcare costs increasing by approximately 
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no significant differences between trial arms in the EQ-5D-3L, SF-36 or Shortened WHO 
Rose Angina Questionnaire.7  
The current report presents a cost-effectiveness analysis comparing BITA grafting with SITA 
grafting for the 3,102 patients in ART. Comparison of the two treatments is made in quality-
adjusted survival, resource use and associated costs across 10-years of follow-up. This is the 
first study to report a randomized comparison of costs and QoL between SITA and BITA 
grafting.  
Methods 
ART randomized patients from 28 centres across seven countries between 2004 and 2007, 
allocating patients to either SITA or BITA. The trial complied with the Declaration of 
Helsinki. Ethics approval for UK centres was obtained from the Multi-Centre Research 
Ethics Committee (MREC), reference number 04/3/006. Prior ethics approval was obtained at 
each non-UK participating centre and every patient was required to provide written informed 
consent. Patients were eligible for the trial if they had multi-vessel coronary artery disease 
and were scheduled to undergo CABG as part of their routine care plan (this included patients 
requiring urgent surgery, but not those with evolving myocardial infarction). Patients 
requiring only single grafts or concomitant valve surgery, as well as those with a history of 
CABG, were excluded. Full details of the trial design including inclusion and exclusion 
criteria and sample size calculations can be found in the trial protocol.8   
Quality of life  
Quality of life data were collected at baseline and each follow-up time point using the 
EuroQol EQ-5D-3L9 and the shortened World Health Organization Rose angina 
questionnaire.10  At baseline, 5 years and 10 years the Medical Outcomes Study 36-Item 
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makes use of responses from the EQ-5D-3L. EQ-5D-3L values were calculated using the 
United Kingdom population tariff with a score of 1 indicating “full health”, 0 death and 
negative values states worse than death.12 Quality adjusted life years (QALYs) for each 
patient were derived by combining survival and quality of life data and then calculating area 
under the curve (AUC) after linear interpolation between time points.  
Resource use and costs  
The perspective of the cost analysis was the English health care system, and other costs were 
not systematically collected. We follow the methods used in several other international 
trials,13,14 by applying a common set of unit costs to all patients, hence results are reported in 
pounds sterling using 2017-18 prices, adjusted where necessary by the GDP deflator index. 
Mean total costs were derived using the cost of the initial hospital admission combined with 
annual costs of healthcare contacts and medications across 10 years of follow-up. The costing 
methodology followed that used in the analyses to 1 year and 5 years of follow-up.5,6 This 
methodology assigned detailed costs to the initial hospital admission, including the total cost 
of surgery, post-operative costs and any in-hospital adverse events (myocardial infarction, 
cerebrovascular accident, further CABG, further PCI, revascularisation with catheter, major 
bleed and the cost of hospital stay associated with other adverse events and death). Unit costs 
were obtained from NHS reference costs where available or from the finance department of 
one participating UK hospital. Supplementary Table S1 documents all unit costs and their 
sources. Reference costs were adjusted for clinical events occurring during the index 
admission to avoid double counting the cost of stay in hospital. 
Resource use data over the 10-year follow-up were collected from case record forms and 
from a short questionnaire at annual follow-up. Data were collected on numbers of GP and 
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admission bed days, medication usage and resource use associated with severe adverse 
events. GP and nurse visits were costed using estimates from the Personal Social Services 
Research Unit while NHS reference costs provided unit costs for all recorded hospital 
outpatient clinic, cardiac rehabilitation clinic visits and costs associated with severe adverse 
events. The cost of adverse events classed as “other” and death were assumed to be captured 
by costing the length of stay of the associated hospital admission. An emergency department 
attendance was assumed where participants were admitted for an event but no overnight stay 
was reported. The cost of hospital bed days was adjusted to avoid double counting those 
associated with “other” adverse events and death. Individual medication usage was costed 
using unit costs from the NHS electronic Market Information Tool (eMIT).  
Cost-effectiveness analyses 
The primary analysis compared patients as randomized on an intention to treat basis. Mean 
resource use items and associated costs, and mean total costs (cost of initial hospital 
admission plus all healthcare contacts and medications across 10 years of follow-up) were 
compared using two-sample t-tests, while Poisson regression models were used to compare 
non-zero counts of adverse events. Standard errors were adjusted to account for clustering at 
the hospital level. Differences in mean QALYs were compared using a linear regression 
model and were adjusted for imbalances in baseline QoL.16 Future QALYs and costs were 
discounted to present values at an annual rate of 3.5%. Incremental cost-effectiveness ratios 
(ICERs) were then calculated from the mean difference in QALYs and costs. Cost-
effectiveness was evaluated assuming a willingness to pay of £20,000 per QALY and at other 
levels.17 The uncertainty surrounding the ICER estimate was characterised using non-
parametric bootstrap replications of the mean difference in QALYs and costs.18 Bootstrap 
samples were taken independently within each treatment group and with resampling at the 
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construct cost-effectiveness acceptability curves, which show the likelihood that the 
intervention is cost-effective as the willingness to pay changes.20 
Around a quarter of patients assigned to the SITA arm of the trial received an additional 
radial-artery graft, while 14% of the BITA group actually underwent SITA grafting. 
Evidence has grown since the trial was designed that radial-artery grafts are associated with 
better clinical outcomes in comparison to saphenous-vein grafts,21 and so a non-randomized 
comparison of patients receiving multiple arterial grafts (MAG) or single arterial grafts 
(SAG) was also made. These groups were well balanced in terms of baseline characteristics.4 
Nonetheless, 1-to-1 propensity score matching was used to adjust total costs for imbalances 
in baseline covariates.  
The cost-effectiveness of BITA compared to SITA arms beyond the 10 years of the trial was 
estimated using a Markov cohort model. Survival in each arm of the trial was estimated using 
Gompertz functions. The first year of trial data was excluded as this improved the fit of the 
functions to the data. Costs and utility were estimated beyond 10 years with linear models 
adjusting for age using data from the last five years of the trial. This allowed for variation in mean 
costs and mean utility by age.Patients begin the model at a mean age of 74 years in line with 
trial participants at 10 years of follow-up, and face an annual probability of death as 
determined by the survival functions. QALYs and costs in the extrapolation were discounted 
at an annual rate of 3.5%. Probabilistic sensitivity analysis (PSA) was conducted to 
characterise the uncertainty around the extrapolation results using 1000 bootstrap samples 
from each imputed dataset. The output from the sensitivity analysis is presented using cost-
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The rate of missing data was low overall but increased over time, with between 3% and 37% 
of some resource use items missing at different time points, and between 9% and 38% of 
QoL data. Missing rates of both resource use and EQ-5D-3L data were similar for BITA and 
SITA groups. 71 patients had missing vital status, and 279 patients had incomplete adverse 
event data. Where clinical outcome data were missing, it was assumed an event had not 
occurred. Logit models of missing total costs and utility across 10 year follow-up on baseline 
variables showed missing data to be associated with baseline hospital and being a smoker or 
former smoker at baseline.  
Imputation was implemented separately by randomized treatment allocation. EQ-5D-3L data 
were missing at baseline for 159 (5.1%) patients: these were imputed using mean imputation.  
All other missing values for both resource use and EQ-5D-3L value data were imputed using 
chained equations and predictive mean matching.22 These equations used baseline hospital, 
age, sex, baseline Canadian Cardiovascular Society (CCS) class, diabetes, smoking status, 
peripheral arterial disease and baseline EQ-5D-3L index. The procedure was repeated to 
produce 50 imputed datasets with Rubin’s Rule used to summarise across imputations.23 The 
non-parametric bootstrap approach used to construct the estimates for the cost-effectiveness 
plan and CEAC drew 1000 samples for each imputed dataset.24   
Sensitivity analyses 
The sensitivity of the results to the missing at random assumption was investigated using a 
pattern mixture model.25 Imputed values were adjusted by a multiplicative scale parameter. 
The included values of the sensitivity parameter varied both imputed costs and QoL to -20% 
of their original value at 5% point intervals. The different missing not at random scenarios 
were then compared in terms of the probability of BITA being cost-effective at a willingness 











The cost-effectiveness of BITA compared to SITA was estimated for all patients and for pre-
specified patient subgroups: diabetic and non-diabetic, age ≥70 years versus <70 years, on-
pump versus off-pump, prior myocardial infarction (MI) versus no prior MI, New York Heart 
Association (NYHA) class I and II versus NYHA class III and IV, and Canadian 
Cardiovascular Society (CCS) class 0, I and II versus CCS class III and IV. Comparison was 
also made in each of the three countries (UK, Poland and Australia) which recruited more 
than 100 patients to the trial. Linear models with interaction terms between subgroup and 
treatment allocation were used to test for significant differences in treatment between 
subgroups, with standard errors again being adjusted for clustering at the hospital level. 
 
Results 
Table 1 shows resource use, the frequency of adverse events and associated mean cost and 
QALYs at 10 years for the two trial arms. BITA grafting was associated with significantly 
larger total mean costs at 10 years of follow-up. This was primarily the result of the 
significantly higher index admission cost in the BITA group. The BITA group also had 
significantly higher mean costs associated with outpatient clinic visits and sternal wound 
problems. There were no significant differences in costs associated with any other healthcare 
contacts, medication usage or adverse events.  
Mean EQ-5D-3L values initially increased following surgery for both treatment groups but 
then decreased as patients aged (Supplementary Table 3). No differences were found between 
the two groups at any time point during the trial (Supplementary Table 3). This was also the 
case using both the SF-36 and Rose Angina Questionnaire (Supplementary Table 4 and 5 
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adjusted life years were small and not statistically significant. Combining the cost (mean 
difference £1,133 95% CI £239 to £2,026, p= 0.015) and QALY (adjusted mean difference -
0.01 95% CI -0.2 to 0.1, p= 0.883) differences, BITA is dominated (more expensive, less 
effective) by SITA. The probability of BITA grafting being cost-effective compared to SITA 
(that is, of having a cost per QALY gained of less than £20,000) was 33% (Figures 1(a) and 
1(b)). 
Table 2 shows summary results on costs, QALYs and cost-effectiveness for each pre-
specified patient subgroup, and Figure 2 shows these sub-group analyses when tested for 
interaction between treatment allocation and cost or QALY differences. Concerning costs, a 
significant interaction with treatment allocation was found for patients with diabetes and for 
patients with a higher baseline severity CCS class, in both cases the cost difference being 
larger. A significant interaction was also found between treatment allocation and NYHA 
class, with classes III and IV being associated with a lower QALY gain: in this group 6.29 
QALYs had been accumulated by 10 years in the SITA group compared to 6.01 in the BITA 
group, a difference of -0.29 (95% CI -0.57, -0.01, p=0.044). Combining these costs and 
QALY differences, SITA dominated BITA (that is, less costly, more health benefit) in 6 sub-
group analyses. Only in the groups with off-pump surgery, no prior MI, less severe NYHA 
and CCS classes and in Poland was the cost of BITA per QALY gained lower than the 
threshold of £20,000, and in none of these groups was the test for interaction between 
treatment allocation and either costs or QALYs significant. Further details of these subgroup 
analyses are provided in supplementary Tables S7-S13. 
Sensitivity analyses in which the assumption that missing data were missing at random was 
replaced with an assumption that missing cost and QALY data might be systematically 
different in either arm of the trial, found that the probability of BITA being cost-effective was 
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For example, a reduction of 10% in the imputed costs in the BITA arm increased the 
probability of BITA being cost-effective from 33% to 39%. In contrast, a decrease in imputed 
QALYs of the same magnitude in the SITA arm increased the probability of BITA being 
cost-effective to 69%. Further results from the sensitivity analysis are shown in Figure S1.  
Results from the non-randomized comparison of multiple versus single arterial grafts are 
shown in Table 3. Multiple arterial grafts were associated with significantly higher costs in 
several resource use categories including the index procedure, GP visits, and treatment for 
sternal wound problems. As a result, total costs were significantly higher over the 10 years of 
follow-up. However, multiple arterial grafts were also associated with longer survival over 10 
years (9.14 years versus 8.94, average treatment effect 0.10, CI -0.09, 0.29, p=0.306), and 
slightly more QALYs were accrued in the MAG group, so that the incremental cost-
effectiveness ratio was £16,812 per QALY gained, with a probability of being cost-effective 
(less than £20,000) of 54%.  
Table 4 shows the results from the extrapolation model. Costs and QoL observed in the trial 
in each group were extrapolated over an expected lifetime, with competing risks in line with 
extrapolated survival, the between-group difference in costs remained similar but the QALY 
gain associated with BITA grafting showed a small increase, primarily attributable to slightly 
lower mortality risk in the BITA arm. This resulted in an ICER of £12,962 per QALY and 
increased the probability of BITA being cost-effective to 51% at a willingness to pay of 
£20,000.  
Discussion  
This is the first study to report a randomized comparison of costs and quality adjusted 
survival between SITA and BITA grafting. We found the higher initial cost of BITA, 
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significant differences were observed in QALYs over the same time period. As a result, the 
probability of BITA being cost-effective at a willingness to pay of £20,000 per QALY gained 
was only around 33%. There were no significant differences in QoL at any time point across 
10 years of follow-up. 
Sub-group analyses 
In our analyses of pre-specified sub-groups, we found a significant interaction between 
treatment allocation and difference in costs for patients with diabetes or who were in a higher 
baseline severity CCS class, both of which were associated with a larger cost difference in 
favour of SITA. Similarly, we found a significant interaction between treatment allocation 
and difference in QALYs for patients in NYHA classes III and IV, such that those allocated 
to SITA accumulated significantly more QALYs over 10 years than those in the BITA group. 
As a result, we found some evidence that BITA grafting was more cost-effective in groups 
with less severe baseline conditions and less cost-effective in groups with more severe 
baseline conditions. Compared to SITA with or without radial artery use, BITA grafting 
requires sequential (as opposed to simultaneous) harvesting of the conduits and increases the 
trauma to the chest wall.  One hypothesis could therefore be that recovery from the increased 
surgical trauma is more prolonged and less complete in patients with marginal functional 
status at baseline, resulting in higher costs and lower quality adjusted survival compared to 
SITA in this group.  
Single versus multiple artery grafts 
The non-randomized comparison of patients who received a single arterial graft with those 
receiving multiple grafts found a survival advantage over 10 years in the MAG group and the 
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for health benefit. These results are suggestive that the use of multiple grafts is preferable to 
single grafts from an economic perspective as well as from a clinical perspective.  
Longer-term costs and benefits 
The costs and benefits of BITA versus SITA beyond 10 years of follow-up remain an 
important question. Previously, Buttar et al conducted a meta-analysis which reviewed both 
long-term and short-term clinical outcomes following BITA and SITA grafting, and reported 
overall survival out to more than 20 years after surgery.3 However, their finding of a 
significantly lower hazard ratio for the BIMA group was based on observational studies, and 
is not confirmed by ART at 10 years. Therefore we chose to extrapolate outcomes and costs 
beyond the end of the trial using a Markov model driven by some fairly simple assumptions 
on how survival, quality of life and costs would evolve over the remaining lifetime of the trial 
participants, drawing on ART data. This analysis indicated that the probability of BITA 
grafting being cost-effective increased to 51%. Continuing follow-up of ART participants 
beyond 10 years would provide valuable data to test the validity of these assumptions.   
Limitations 
The overall level of attrition in the ART trial was exceptionally low,4 but the economic 
analysis, drawing on many different aspects of trial data including questionnaires, case record 
forms, quality of life and resource use measures and all time points, did face a degree of 
missing data.  We followed best practice in relying primarily on multiple imputation methods 
to deal with this, and tested the methods using sensitivity analysis. This indicated that the 
results were robust to large changes in the level of the imputed cost data. However, the 
results were more sensitive to changes in the values of imputed quality of life data. This is a 
common result in sensitivity analysis of imputed data in trial based cost-effectiveness 
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ART was an international study, enrolling patients from 7 countries.  We conducted this 
analysis from the perspective of the UK only, applying UK unit costs and quality of life 
valuations to all observed data. This approach has been adopted in a number of other 
international trial analyses,13 two-thirds of all ART patients were recruited in the UK, and the 
subgroup analyses found no significant interactions between treatment allocation and country 
for costs or QALYs. However, it remains possible that the results were influenced by 
variations in treatment pathways between countries.  
Although our sub-group analyses were suggestive that BITA grafting was more cost-effective 
in groups with less severe baseline conditions, it is possible that these results arise from 
confounding: for example, approximately 22% of patients in NYHA classes I & II had a 
radial artery graft compared to 17% in classes III & IV. Similarly, the proportion of patients 
with ejection fraction <50% was 26% in NYHA classes I & II compared with 31% in classes 
III & IV.  
More generally, the results of the ITT analysis of ART may have been affected by important 
confounders such as the high crossover rate and the high use of the radial artery in both 
groups.26  
Finally, while the results of our as-treated analysis support use of multiple arterial over single 
grafts from an economic as well as a clinical perspective, we acknowledge that the limitations 
of   non-randomized comparisons may have biased this result. A randomized comparison of 
multiple arterial and single grafts will be provided by the ROMA trial.27      
Conclusions 
We found that BITA grafting incurs higher costs than SITA during the initial procedure 
which are not offset by cost savings in later years. There are no significant differences in 
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compared to SITA at 10 years is low. However, our extrapolation suggested that BITA may 
become more cost-effective over a lifetime horizon. Uncertainty surrounding our 
extrapolation results can best be reduced by continuing to follow up ART patients for as long 
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Table 1: Resource use, costs, quality adjusted life years and cost-effectiveness at 10 year follow-up (Intention-to-Treat Analysis) 
 Mean resource use / adverse events at year 10 Mean total cost at year 10 
 
SITA 
 (n =1554) 
BITA 
 (n=1548) 
BITA vs SITA 
Mean difference (95% 
CI, p value) 
SITA 
 (n =1554) 
BITA 
 (n=1548) 
BITA vs SITA 
Mean difference (95% CI, 
p value) 
Initial surgery       
Index admission    8819 9475 656 (101, 1212; 0.023) 
Discharge cost    562 532 -30 (-353, 292; 0.848) 
Healthcare contacts       
GP visits 32 31 -0.67 (-2, 1; 0.461) 1424 1405 -19 (-100, 61; 0.627) 
Nurse visits 14 14 0.26 (-1, 2; 0.772) 231 234 3 (-19, 25; 0.784) 






niversity of East Anglia user on 02 February 2021
Cardiac rehabilitation visits 10 10 -0.58 (-3, 2; 0.659) 779 736 -43 (-316, 230; 0.750) 
Number of nights in hospital* 2 2 0.42 (-0, 1; 0.196) 716 875 159 (-163, 481; 0.318) 
All health care contacts    4689 4934 245 (-103, 594; 0.159) 
Medications       
Total medication 35 35 -0.09 (-1, 1; 0.881) 218 222 5 (-6, 16; 0.383) 
SAE treatment †       
Myocardial infarction 53 52 0.98 (0.7, 1.4; 0.938) 74 67 -7 (-36, 22; 0.633) 
Cerebrovascular accident 63 45 0.72 (0.5, 1.1; 0.088) 129 87 -42 (-94, 10; 0.111) 
Further CABG 0 3 . 0 14 14 (-4, 31; 0.127) 
Further PCI 157 154 0.98 (0.8, 1.2; 0.892) 302 300 -2 (-76, 73; 0.965) 
Revascularisation with catheter 82 79 0.97 (0.7, 1.3; 0.832) 100 107 7 (-46, 60; 0.784) 
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Major bleeding 11 10 0.91 (0.4, 2.1; 0.834) 48 70 22 (-49, 93; 0.537) 
Other AEs (cost of hospital stay 
only) 
1506 1749 1.17 (1.1, 1.2; 0.000) 
2201 2377 176 (-322, 675; 0.474) 
Death (cost of hospital stay only) 314 297 0.95 (0.8, 1.1; 0.522) 405 363 -41 (-262, 179; 0.703) 
All adverse event costs    3360 3662 302 (-290, 894; 0.304) 
All costs    17647 18825 1178 (204, 2152; 0.020) 
       
Discounted total cost    16462 17594 1133 (239, 2026; 0.015) 
       
Life years    9.03 9.05 0.02 (-0.15, 0.20; 0.801) 
QALYs ‡    6.57 6.54 -0.01 (-0.2, 0.1; 0.883) 
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Incremental cost-effectiveness 
ratio: 
     
BITA dominated (more 
expensive, less effective 
(non-significant)) 
Probability of cost-effectiveness 
at willingness to pay threshold 
of:                          £13,000 




                               £20,000      33% 
                               £30,000      36% 
The cost of index admission includes the total cost of surgery (Time in theatre (minutes), duration related theatre costs and staff, duration related 
anaesthetic costs, time on bypass (minutes), and other surgery costs (consumables, blood products, aprotinin),  post-operative costs (Ventilation 
time, Intra-aortic balloon pump, Inotropic support, Renal support therapy, Hemofiltration) and any in hospital adverse events (Myocardial 
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only), Death (cost of hospital stay only)).  
* Number of nights in hospital exclusive of those associated with an "other" adverse event or death.  
† SAE treatment is that occurring in the follow-up period only. The cost of SAEs which occurred during the index admission is included in the 
cost of index admission.  
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Table 2 Total costs, QALYs and cost-effectiveness at 10 year follow-up by patient subgroup 
 Total cost (£) QALYs   
 SITA BITA BITA vs SITA 
Mean difference 
(95% CI, p value) 
SITA BITA BITA vs SITA* 
Mean difference 
(95% CI, p value) 
ICER Pr CE 
No history of 
diabetes (n=2368) 
16354 16970 
616 (-479, 1711; 
0.257) 
6.67 6.61 
-0.032 (-0.19, 0.13; 
0.688) 
Dominated** 34% 
Diabetes (n=734) 17378 20164 
2786 (1072, 4499; 
0.003) 
6.23 6.32 
0.061 (-0.35, 0.47; 
0.760) 
45642 39% 
Aged < 70 Yrs 
(n=2271) 
15411 16686 
1275 (535, 2015; 
0.002) 
6.76 6.78 
0.018 (-0.16, 0.19; 
0.836) 
72840 39% 
Aged >= 70 Yrs 
(n=831) 
19723 20688 
964 (-1248, 3176; 
0.375) 
6.06 5.89 
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Off-pump (n=1259) 17434 17815 
382 (-731, 1495; 
0.481) 
6.51 6.52 
0.027 (-0.20, 0.26; 
0.805) 
13903 51% 
On-pump (n=1819) 16134 17898 
1764 (317, 3211; 
0.019) 
6.65 6.64 
-0.002 (-0.21, 0.21; 
0.986) 
Dominated** 32% 
No prior MI 
(n=1800) 
16562 17048 
486 (-690, 1662; 
0.402) 
6.65 6.65 
0.026 (-0.18, 0.23; 
0.794) 
18903 49% 
Prior MI (n=1300) 16639 18718 
2079 (676, 3483; 
0.005) 
6.46 6.38 
-0.079 (-0.28, 0.12; 
0.430) 
Dominated** 19% 
 NYHA class I & II 
(n=2431) 
16572 17391 
819 (-99, 1737; 
0.078) 
6.64 6.70 
0.071 (-0.08, 0.22; 
0.338) 
11496 56% 
NYHA class III & 
IV (n=669) 
16669 18939 
2270 (-75, 4615; 
0.057) 
6.29 6.01 
-0.290 (-0.57, -0.01; 
0.044) 
Dominated** 15% 
CCS class 0, I, II 
(n=2143) 
16701 17106 
405 (-763, 1573; 
0.482) 
6.65 6.67 
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CCS class III, 
IVa/b/c (n=959) 
16349 19113 
2764 (852, 4676; 
0.006) 
6.40 6.27 
-0.132 (-0.42, 0.16; 
0.353) 
Dominated** 20% 
UK (n=2053) 17365 18384 
1019 (-439, 2476; 
0.154) 
6.40 6.40 
0.024 (-0.19, 0.24; 
0.810) 
42481 40% 
Poland (n=606) 14658 15664 
1006 (-72, 2084; 
0.061) 
6.79 6.96 
0.202 (-0.06, 0.46; 
0.091) 
4986 65% 
Australia (n=192) 18444 19027 
584 (-2073, 3240; 
0.665) 
6.59 6.54 
-0.058 (-0.65, 0.53; 
0.846) 
Dominated** 39% 
*Estimated differences in QALYs are adjusted for baseline EQ-5D-3L index 
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Table 3 Resource use, costs, quality adjusted life years and cost-effectiveness at 10 year follow-up (non-randomised comparison of 
multiple versus single arterial graft) 
 Mean resource use / n of adverse events at year 10 Mean total cost at year 10 




SAG vs MAG 






SAG vs MAG 
Average treatment effect 
(95% CI, p value) 
Initial surgery       
Index admission    8818 9509 641 (195, 1088; 0.005) 
Discharge cost    647 480 -132 (-418, 153; 0.363) 
Healthcare contacts       
GP visits 30 33 3 (1, 5; 0.001) 1348 1466 115 (28, 202; 0.010) 
Nurse visits 14 13 -1 (-2, 1; 0.521) 239 226 -18 (-47, 12; 0.240) 
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Cardiac rehabilitation visits 9 10 1 (-1, 4; 0.308) 698 805 98 (-106, 301; 0.347) 
Number of nights in 
hospital * 
2 2 0.4 (-0, 1; 0.222) 
711 870 193 (-92, 478; 0.184) 
All health care contacts    4593 4998 416 (-38, 870; 0.073) 
Medications       
Total medication 35 36 2 (0, 3; 0.017) 218 222 4 (-10, 17; 0.589) 
SAE treatment †       
Myocardial infarction 38 64 1.33 (0.9, 2.0; 0.169) 62 78 31 (-4, 67; 0.086) 
Cerebrovascular accident 55 52 0.74 (0.5, 1.1; 0.126) 122 101 -25 (-86, 37; 0.433) 
Further CABG 0 3 . 0 12 14 (-7, 34; 0.181) 
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Revascularisation with 
catheter 
75 78 0.82 (0.6, 1.1; 0.215) 
106 99 -9 (-60, 43; 0.740) 
Sternal wound problems 34 73 1.69 (1.1, 2.5; 0.012) 95 264 45 (-153, 244; 0.656) 
Major bleeding 9 11 0.96 (0.4, 2.3; 0.931) 53 65 -9 (-90, 71; 0.824) 
Other AEs (cost of hospital 
stay only) 
1283 1871 1.15 (1.1, 1.2; 0.000) 
2013 2504 567 (-227, 1360; 0.162) 
Death (cost of hospital stay 
only) 
298 293 0.77 (0.7, 0.9; 0.002) 
436 352 -58 (-299, 183; 0.637) 
All adverse event costs    3201 3763 523 (-458, 1504; 0.296) 
All costs    17478 18972 1451 (99, 2803; 0.035) 
       
Discounted total cost    16367 17681 1251 (63, 2438; 0.039) 
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Life years    8.94 9.14 
0.10 (-0.09, 0.29; 0.306) 
 
QALYs ‡    6.51 6.67 0.08 (-0.1, 0.2; 0.380) 
ICER    16,412   
Probability of cost-
effectiveness 
   54%   
*Number of nights in hospital exclusive of those associated with an "other" adverse event or death.  
† SAE treatment is that occurring in the follow-up period only. The cost of SAEs which occurred during the index admission is included in the 
cost of index admission.  
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Table 4 Lifetime cost-effectiveness (extrapolation) of BITA versus SITA (intention to 
treat analysis) 
  SITA 
 (n =1554) 
BITA 
 (n=1548) 
BITA vs SITA 
Cost (£) £21,829 £22,707 £ 1,165 
QALYs 12.52 12.61 0.09 
Life years 17.65 17.89 0.24 
ICER 12,962 
















Figure 1: a) Cost-effectiveness plane and b) cost-effectiveness acceptability curve at 10 years 
of follow-up.  
 
 
Caption: Figure 1a plots a series of simulations showing the likelihood that BITA yields more 
or fewer quality adjusted life years than SITA (X-axis), and costs more or less than SITA (Y-
axis). Co-ordinates to the left and above the dashed line have a cost-effectiveness ratio above 
£20,000 per QALY gained; those to the right and below the line are less than £20,000 per 
QALY gained.  Figure 1b shows the probability that BITA is cost-effective compared to 
SITA as the willingness to pay for each QALY gained is varied from £0 to £100,000, that is, 
as the dashed line is rotated around the origin.     
 
Figure 2 
Figure 2: Interaction between selected subgroups and treatment. *Estimated differences in 
QALYs are adjusted for baseline EQ-5D-3L value. 
 
Caption: Figure 2 shows how the observed difference in costs and in QALYs 
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Items to include when reporting economic evaluations of health interventions 
 
The ISPOR CHEERS Task Force Report, Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations 
Publication Guidelines Good Reporting Practices Task Force, provides examples and further discussion of 
the 24-item CHEERS Checklist and the CHEERS Statement.   It may be accessed via the Value in Health or 







on page No/ 
line No 
Title and abstract 
Title 1 Identify the study as an economic evaluation or use more 
specific terms such as “cost-effectiveness analysis”, and 
describe the interventions compared.  P1 title, P3 Objectives
Abstract 2 Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), results      P3 Abstract





3 Provide an explicit statement of the broader context for the 
study. 
 P6-7 Introduction
Present the study question and its relevance for health policy or 
practice decisions.  
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen.  P7 Methods
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) 
need(s) to be made.  P8 Methods
Study perspective 6 Describe the perspective of the study and relate this to the 
costs being evaluated.  P8 Methods
Comparators 7 Describe the interventions or strategies being compared and 
state why they were chosen.  P6 Introduction
Time horizon 8 State the time horizon(s) over which costs and consequences 
are being evaluated and say why appropriate. 
 
 P8 & 10
Discount rate 9 Report the choice of discount rate(s) used for costs and  
outcomes and say why appropriate.  P10
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the type of 
analysis performed.  P7
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the single 








niversity of East Anglia user on 02 February 2021






11b Synthesis-based estimates: Describe fully the methods used for 
identification of included studies and synthesis of clinical 
effectiveness data.  N/A
Measurement and 
valuation of preference 
based outcomes 
12 If applicable, describe the population and methods used to 




13a Single study-based economic evaluation: Describe approaches 
used to estimate resource use associated with the alternative 
interventions. Describe primary or secondary research methods 
for valuing each resource item in terms of its unit cost. 
Describe any adjustments made to approximate to opportunity  P8-9 Resource use & costs
costs.  
13b Model-based economic evaluation: Describe approaches and 
data sources used to estimate resource use associated with 
model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit        (not mainly a model:  
cost. Describe any adjustments made to approximate to           details on P10)
opportunity costs.  
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource quantities and unit 
costs. Describe methods for adjusting estimated unit costs to 
the year of reported costs if necessary. Describe methods for   P8 resource use & costs
converting costs into a common currency base and the 
exchange rate.  
Choice of model 15 Describe and give reasons for the specific type of decision-
analytical model used. Providing a figure to show model        P10 Markov - but not 
structure is strongly recommended.                                         primary analysis       
Assumptions 16 Describe all structural or other assumptions underpinning the 
decision-analytical model. P10 
Analytical methods 17 Describe all analytical methods supporting the evaluation. This 
could include methods for dealing with skewed, missing, or 
censored data; extrapolation methods; methods for pooling 
data; approaches to validate or make adjustments (such as half 
cycle corrections) to a model; and methods for handling          P10 Missing data
population heterogeneity and uncertainty.  P11 Subgroups
Results 
Study parameters 18 Report the values, ranges, references, and, if used, probability 
distributions for all parameters. Report reasons or sources for 
distributions used to represent uncertainty where appropriate.    N/A
Providing a table to show the input values is strongly 
recommended.  
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, as well   P12-14 
as mean differences between the comparator groups. If        Tables 1-4
applicable, report incremental cost-effectiveness ratios.  
Characterising 
uncertainty 
20a Single study-based economic evaluation: Describe the effects 
of sampling uncertainty for the estimated incremental cost and 







niversity of East Anglia user on 02 February 2021






of methodological assumptions (such as discount rate, study 
perspective). 
20b Model-based economic evaluation: Describe the effects on the 
results of uncertainty for all input parameters, and uncertainty 
related to the structure of the model and assumptions.  N/A
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between 
subgroups of patients with different baseline characteristics or   Table 2 &
other observed variability in effects that are not reducible by 






22 Summarise key study findings and describe how they support 
the conclusions reached. Discuss limitations and the 
generalisability of the findings and how the findings fit with 
current knowledge.  P14-17 Discussion
Other 
Source of funding 23 Describe how the study was funded and the role of the funder 
in the identification, design, conduct, and reporting of the 
analysis. Describe other non-monetary sources of support.  P19 Sources of funding
Conflicts of interest 24 Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the absence  ICMJE
of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors 
recommendations.  
 
For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT 
statement checklist 
 
The ISPOR CHEERS Task Force Report provides examples and further discussion of the 24-item 
CHEERS Checklist and the CHEERS Statement.   It may be accessed via the Value in Health link or via the 
ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices 
webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp 
 
The citation for the CHEERS Task Force Report is: 
Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards 
(CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication 
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